Fit-for-Purpose Biomarker Development Framework

This white paper outlines the framework for fit-for-purpose biomarker development within the context of drug discovery and clinical research. It describes the role of target engagement biomarkers, which are critical in the early phases of clinical research, and differentiates them from disease-related biomarkers. The document emphasizes the importance of biomarkers in assessing drug efficacy and safety, particularly in early clinical trials where traditional clinical outcomes may be difficult to measure. It details the processes of biomarker qualification, evaluation, and validation, highlighting the need for validated quantification methods to link biomarkers with biological processes and clinical endpoints. The paper also discusses the FDA's guidelines on biomarker qualification and the distinct categories of biomarkers defined by the FDA. These categories include susceptibility, diagnostic, monitoring, prognostic, predictive, pharmacodynamic, and safety biomarkers, each serving different roles in the drug development process. The iterative nature of validation and qualification is emphasized as essential for ensuring clinical utility.